Eric Fischer
Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.
Daniel Nomura
Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies.
Anne Bertolotti
Anne obtained her Ph.D. from Strasbourg University (France), and did a post doc at The Skirball Institute of Biomolecular Medicine, NYU, New York. She has been a group leader at the MRC Laboratory of Molecular Biology since 2006. She was an INSERM Investigator from 2000 to 2006, was elected an EMBO Young Investigator in 2005, was awarded an ERC consolidator grant in 2013, became and EMBO member in 2013 and won the Hooke Medal in 2014. In 2017, she became a Fellow of the National Academy of Medical Sciences in the UK and was awarded a Wellcome Trust Investigator Award. In 2018, she won the GlaxoSmithKline Award from the Biochemical Society.
Anne has made seminal contributions to our current understanding of protein quality control mechanisms in cells, which represent the cellular defence systems against potentially harmful proteins. She was one of the pioneer in the discovery of mammalian unfolded protein response and more recently discovered the pathways by which cells maintain proteasome homeostasis.
She has also identified mechanisms underlying the deposition of misfolded proteins in neurodegenerative diseases and contributed to a dogmatic shift in this field with the discovery that mutant SOD1 aggregates propagate indefinitely just like prions.
With the knowledge acquired on protein quality control systems, Anne identified strategies to boost their function and is currently exploiting them for the treatment of neurodegenerative diseases. One of the strategy consists in selective inhibition of a phosphatase, an important advance because phosphatases were thought to be undruggable.
Craig Crews
Dr. Crews is the Lewis Cullman Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U. Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory pioneered the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new ‘induced protein degradation’ drug development technology, PROTACs, which served as the founding IP for his latest New Haven-based biotech venture, Arvinas, Inc. From 2008 to 2018, Dr. Crews served an Editor of Cell Chemical Biology and he currently serves on several editorial boards. In addition, he has received numerous awards and honors, including the CURE Entrepreneur of the Year Award (2013), Ehrlich Award for Medicinal Chemistry (2014), Yale Cancer Center Translational Research Prize (2015), a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017), the Khorana Prize from the Royal Society of Chemistry( 2018), the Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019) and was named an American Cancer Society Professor in 2018.
Bruce E. Teitelbaum
Bruce E. Teitelbaum founded RPG, rpg57.com, in New York City in 1991. RPG is an award-winning design/build firm globally recognized for its ability to invigorate the brick-and-mortar experience, elevate and reinforce the power of brands, and compel consumers to shop and purchase. RPG maintains an unwavering commitment to quality and innovation. Through Bruce’s leadership, RPG exceeds industry standards of excellence, with headquarters in Manhattan and global manufacturing facilities. RPG is recognized as an industry expert, with blue chip clients around the world.
Bruce and Dr. Julie Bartholomew co-founded RPG x IMX, rpximx.com, in 2017. Under this partnership, RPG x IMX leverages its intellectual property of more than 75 granted patents along with the founders’ long-established histories as innovators in the customization of cosmetics and consumer experiences. Their unique technology solutions dramatically re-focus shopping behavior to be tailored towards entirely personalized products and customized experiences. The transformative alliance of RPG x IMX offers real-time, in-store customization never before realized, turning passive consumers into active, highly engaged buyers.
Michael Cade
Michael Cade is a Global Technologist for Veeam Software. Based in the UK, an IT Professional with over 14 years of industry experience with a key focus on Data Center technologies including Virtualisation, Storage and Data Center. Michael’s role at Veeam is to engage those new to availability technologies as well as those who are experts, speaking at events and sharing the Veeam vision and strategy of the company whilst providing feedback from the field into product management to shape the future success of Veeam Software.
Michael is very active around the social media sphere blogging and tweeting relevant technical content.
Kuan Hon
I am a director in the Privacy, Security and Information group at Fieldfisher, focusing on data protection law and information law.
As I have a computing science degree and a passion for technology (especially technical security aspects), I enjoy working on projects relating to new and emerging technologies such as cloud computing and IoT. I also advise clients on security breaches and other security-related matters, such as NIS Directive issues.
Aubrey Stearn
Aubrey is currently CTO of the Nationwide Digital Accelerator Platform, she deeply believes that the DevOps movement redefines what we need to nurture and grow in our current and future engineers, actives seeks to build super awesome teams of excellent people.
Emmanuel Rey
French-born and one of nine siblings, Emmanuel Rey obtained a degree in engineering in agronomics, and in 2017 founded YUNI Beauty, and at the end of 2018, in a competitive group with Ouai hair care and Youth the people, YUNI received the Rising Brand of the Year Award from the Los Angeles Business Journal.